Andere talen BiVictriX Therapeutics plc

Aandelen

BVX

GB00BNXH3K91

Beurs gesloten - London S.E. Andere beurzen 17:35:18 01-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
12,5 ^GBX	0,00%		0,00%	+19,05%

21/06	BiVictriX Therapeutics Plc rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
13/06	WINST EN HANDEL: Dialight handelt in lijn; Petards boekt verlies	AN

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023	21/06
EARNINGS AND TRADING: Dialight trades in line; Petards swings to loss	13/06
BiVictriX Therapeutics' Leukemia Treatment Shows Favorable Safety Profile	13/06
BiVictriX Therapeutics Plc Announces Compelling Safety Profile of BVX001 in Pre-Clinical Models Supports Progression to Clinic	13/06
BiVictriX Wins Development Grant for Ovarian Cancer Drug Conjugate	06/06
BiVictriX Therapeutics plc Receives Grants to Accelerate Solid Tumour Targeting ADC Pipeline from Innovate UK	06/06
EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend	31/05
Bivictrix granted FDA orphan drug status for rare cancer treatment	17/04
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	17/04
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	05/12
Bivictrix selects final sequences for lead tumour programme	30/11
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	30/11
BiVictriX patent boost; 4Global deal extended	15/11
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	15/11
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	15/11
Bivictrix says BVX001 increases survival rates by more than double	12-10-23
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	12-10-23
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	12-10-23
BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts	06-10-23
Bivictrix hires new CFO as Alex Hughes steps down after seven months	03-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BiVictriX Therapeutics plc

Aandelen

BVX

GB00BNXH3K91

Andere talen

Filters